Sellas Life Sciences Holds Its Breath as a Leukemia Trial Nears the Finish Line

The stock of Sellas Life Sciences has become a high-wire act, driven by a single, narrowing countdown: just two more patient deaths are needed in its pivotal Phase 3 REGAL trial before the database locks and the final analysis begins. As of the company’s latest update in June 2026, 78 of the required 80 overall survival events have been recorded. Until the 80th event is confirmed, the shares remain hostage to speculation, swinging violently on every whisper and trading day.

The extreme price action tells the story. Last Friday, the stock fell 4.64 % to €11.30, but over the past month it has surged more than 82 %, and over the trailing twelve months the gain exceeds 597 % — a reflection of the binary wager that has turned Sellas into one of the sector’s most volatile names. Annualized volatility now stands at 127 %.

A Cash Cushion While the Clock Ticks

Unlike many small-cap biotechs that run out of runway just as a crucial readout looms, Sellas has built a financial buffer. At the end of the first quarter, the company held $107.1 million in cash and equivalents. An additional $28.7 million flowed in during April and May from exercised warrants. Management also maintains an at-the-market (ATM) equity facility that can raise up to $150 million, though it has not yet been tapped. That liquidity should be sufficient to see the company through the FDA approval process — a Biologics License Application (BLA) submission — and even a potential commercial launch, should the data support it.

Two Scenarios, One Outcome

The bull case rests on the interpretation that the delay in reaching the 80th event is itself a positive signal. If the experimental drug galinpepimut-S (GPS) is genuinely extending the median overall survival of acute myeloid leukemia patients in second complete remission beyond historical benchmarks, then the wait becomes a testament to efficacy. The company’s management has called the prolonged interval a “deeply positive signal.” If the unblinded data confirm a statistically significant survival advantage over best available therapy, Sellas could bring the first approved maintenance treatment for this specific AML subgroup to market.

The bear case is equally clear: the delay may be nothing more than a statistical artifact of study design, and the binary nature of event-driven trials means the stock could collapse if the primary endpoint is missed. The shares currently trade 25.9 % below their 52‑week high of €15.25, reached on June 30 — a pullback that some savvy investors may be interpreting as a sign that institutional money is already de‑risking ahead of the readout. Should the trial fail, Sellas would be forced to fall back on its early‑stage pipeline, led by the CDK9 inhibitor SLS009, which has only just begun dosing in a Phase 2 study for newly diagnosed AML patients — a far less mature asset than REGAL.

Should investors sell immediately? Or is it worth buying Sellas Life Sciences?

Analyst Views Diverge

Wall Street is split, reflecting the binary nature of the bet. Alliance Global analyst James Molloy raised his price target to $25 per American Depositary Share in early July and maintained a Buy rating, arguing that the delayed readout actually supports the drug’s efficacy. The consensus among analysts covering the U.S. listing, however, pegs the average target at €15.33 — roughly 35.6 % above Friday’s close. The wide range underscores that the eventual number of events will determine the stock’s direction more than any spreadsheet model.

The Technicals: Holding Above a Key Floor

Despite the recent pullback, the stock remains about 45 % above its 50‑day moving average of €7.81, a level that many traders will watch as a support threshold. As long as that technical line holds, the medium-term trend is intact. But the interim period before the formal confirmation of the 80th event is likely to remain choppy, fueled by rumor and hedging activity.

What Comes Next

The immediate catalyst is a regulatory filing or press release officially confirming the 80th overall survival event. Only after that will the data be unblinded and the statistical analysis proceed. A top‑line result is expected in the second half of 2026 — likely late in the third quarter or the fourth. If the data hit the pre‑specified efficacy hurdles, the narrative will shift quickly toward a BLA submission or even a buyout scenario. If they do not, attention will pivot to SLS009, which also has initial readouts slated for the end of 2026.

For now, Sellas Life Sciences remains a stock whose fate is measured in two remaining events. Every additional day of waiting amplifies both the hope and the risk — and keeps the shares on a knife’s edge between a breakthrough and a breakdown.